1099-1069/asset/HON_left.gif?v=1&s=d87f3b2696ccc0dedb2d500a48bb5dc4ee9ac4e1)
1099-1069/asset/HON_right.gif?v=1&s=193f0d505463b12e551fb780235d2c9eaa727164)
Review Article
You have free access to this content
Extranodal NK/T-cell lymphoma: diagnosis and treatment cues
Article first published online: 19 FEB 2008
DOI: 10.1002/hon.847
Copyright © 2008 John Wiley & Sons, Ltd.
1099-1069/asset/cover.gif?v=1&s=4ed56ff6292a886bbae0f3c5a756507da24e8d15 "Hematological Oncology")
Additional Information
How to Cite
Suzuki, R., Takeuchi, K., Ohshima, K. and Nakamura, S. (2008), Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol. Oncol., 26: 66–72. doi: 10.1002/hon.847
Publication History
- Issue published online: 28 MAY 2008
- Article first published online: 19 FEB 2008
- Manuscript Accepted: 31 DEC 2007
- Manuscript Revised: 9 DEC 2007
- Manuscript Received: 19 JUN 2007
References
- 1, , . Extranodal NK/T-cell lymphoma, nasal type. In World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, JaffeES, HarrisNL, SteinH, VardimanJW (eds). IARC Press: Lyon, France, 2001; 204–207.
- 2. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996; 87: 1207–1210.
- 3. Leukemia and lymphoma of natural killer lineage cells. Int J Hematol 2003; 78: 18–23.
- 4Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 2000; 50: 696–702.
- 5, , , et al. Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan: with special reference to T-cell lymphoma. Ann Oncol 2004; 15: 1091–1096.
- 6, , , et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of ten years. Ann Oncol 2005; 16: 206–214.
- 7, , , et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Cancer 1998; 83: 806–812.
- 8, . Characteristics and uses of natural killer cells. Immunol Today 1998; 9: 291–293.
- 9, . Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421–2438.
- 10, , , , . Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med 1994; 180: 569–576.
- 11, , , . Lymphokine requirement for the generation of natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1995; 85: 3538–3546.
- 12, , , et al. Nasal T-cell lymphoma as a type of so-called “lethal midline granuloma”. Cancer 1982; 50: 2336–2344.
- 13, , , . Most nasal/nasopharyngeal lymphomas are peripheral T-cell neoplasms. Am J Surg Pathol 1987; 11: 418–429.
- 14, , . Expression of natural killer cell markers in non-Hodgkin's lymphomas. Hum Pathol 1987; 18: 1257– 1262.
- 15, , , et al. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: A distinct hematolymphoid disease entity. Blood 1997; 90: 2417–2428.
- 16, , , et al. Prognostic significance of CD7+ CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0. Int J Hematol 2003; 77: 482–489.
- 17, . Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res 1999; 23: 615–624.
- 18, , , et al. Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer 2005; 104: 1022–1031.
- 19, , , et al. Clinical and biologic features of CD4+ CD56+ malignancies. Blood 2002; 99: 1556–1563.
- 20, , , et al. ‘Agranular CD4+ CD56+ hematodermic neoplasm’ (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002; 26: 852–862.
- 21, , , . Aggressive NK-cell leukemia. In World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, JaffeES, HarrisNL, SteinH, VardimanJW (eds). IARC Press: Lyon, France, 2001; 198–200.
- 22, , , et al. Aggressive natural killer (NK)-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18: 763–770.
- 23, , , , , . Natural killer (NK)-cell neoplasms: aggressive NK-cell leukemia and extranodal NK-cell lymphoma, nasal type. Ann Oncol 2005; 16 (Suppl. 5): v129–v130 [Abstract # 315].
- 24, , , et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995; 13: 666–670.
- 25, , , et al. CD5- CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 1996; 87: 1466–1473.
- 26, , , et al. Clinicopathologic study of nasal T/NK-cell lymphoma among the Japanese. Pathol Int 1997; 47: 38–53.
- 27, , , et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97: 821–829.
- 28, , , , , . Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer 1997; 80: 477–488.
- 29, , , et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70–77.
- 30, , , , , . Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 2000; 89: 2106–2116.
- 31, , , et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004; 100: 366–375.
- 32, , , et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 2004; 103: 216–221.
- 33, , , et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004; 15: 618–625.
- 34, , , et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type. Blood 2005; 106: 3785–3790.
- 35, , , et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612–618.
- 36
- 37, , , et al. Nasal T/NK cell lymphomas commonly express perforin and Fas ligand: important mediators of tissue damage. Histopathology 1997; 31: 444–450.Direct Link:
- 38, , , et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 103–111.
- 39, , , et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.
- 40, , , . Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Am J Clin Pathol 2001; 115: 266–270.
- 41, , , et al. Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. Clin Cancer Res 2007; 13: 3250–3254.
- 42, , , et al. Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood 1994; 83: 2255– 2260.
- 43, , , et al. Discordant reaction of Leu4 and rabbit anti-human CD3 epsilon in sinonasal ‘T’-cell lymphoma. Int J Hematol 1993; 59: 25–30.
- 44, , , et al. Expression of perforin in nasal lymphoma. Am J Pathol 1996; 149: 699–705.
- 45, , . Discordant CD3 expression in lymphomas when studied on frozen and paraffin sections. Hum Pathol 1995; 26: 1139–1143.
- 46, , , et al. Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis. Head Neck 2004; 26: 584–593.
- 47, , , , . Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 1994; 8: 823–826.
- 48, , , et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21–26.
- 49, , , et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001; 12: 349–352.
- 50, , , et al. Treatment outcome of nasal NK-cell lymphoma: a report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematop 2001; 41: 93–99.
- 51, , , et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995; 76: 2351–2356.
- 52, , , , . P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, P SC83. Blood 1999; 93: 599–606.
- 53, , , et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000; 18: 54–63.
- 54, , , et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 2006; 106: 609–615.
- 55, , , et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 2001; 15: 1123–1126.
- 56, , , et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006; 24: 181–189.
- 57, , , , , . Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol 2003; 20: 13–17.
- 58, , , . L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001; 74: 447–450.
- 59, , . L-asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol 2003; 78: 248–250.
- 60, , , et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma 2003; 44: 879–882.
- 61, . The best way to use asparaginase in childhood acute lymphatic leukaemia–still to be defined? Br J Haematol 2004; 125: 117–127.
- 62, . Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166–178.
- 63, , , et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 2003; 78: 163–167.
- 64, , , et al. Phase I study of SMILE chemotherapy for advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma/leukemia. Cancer Sci 2008 (in press).
- 65, , , et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003; 14: 1673–1676.
- 66, , , et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 2006; 37: 425–431.
- 67, , , et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant 2006; 37: 819–824.
- 68, , , et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130: 561–567.
- 69, , , et al. Epstein–Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 1990; 335: 128–130.
- 70, , , et al. Detection of Epstein–Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am J Surg Pathol 1994; 18: 938–946.
- 71, , , et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003; 63: 2028–2032.
- 72, , , , . Diagnostic and prognostic implications of circulating cell-free Epstein–Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res 2002; 8: 29–34.
- 73, , , , . Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004; 104: 243–249.
- 74, , . Toward standardization of Epstein–Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 2001; 39: 1211–1216.